Forecast: Re-Import of Vaccines for Human Use to the UK 2023 - 2027 Discover more data with ReportLinker!

Snapshot img

Vaccine Research Market Size 2024-2028

The vaccine research market size is forecast to increase by USD 21.4 billion, at a CAGR of 10.84% between 2023 and 2028.

The market is driven by the high prevalence of infectious diseases worldwide, necessitating the continuous development of new and effective vaccines. The adoption of artificial intelligence (AI) in vaccine research is a significant trend, accelerating the R&D process and enabling the discovery of potential vaccine candidates more efficiently. However, the market faces substantial challenges, including the high cost of vaccine research, development, and manufacturing, which can hinder the entry of new players and limit the market's growth potential. Companies seeking to capitalize on market opportunities must navigate these challenges effectively, focusing on cost reduction strategies and collaborations to share resources and expertise.
Additionally, staying abreast of the latest technological advancements in vaccine research, such as AI and gene editing, can provide a competitive edge in this dynamic market.

What will be the Size of the Vaccine Research Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2018-2022 and forecasts 2024-2028 - in the full report.
Request Free Sample

The market continues to evolve, driven by the ongoing need for epidemic and pandemic preparedness. This dynamic landscape encompasses various sectors, including cold chain technology, public health, drug discovery, and inactivated vaccines. In this context, continuous research and development efforts are underway to address the challenges of supply chain management, manufacturing processes, and regulatory approval. In the realm of inactivated vaccines, in-vivo studies and in-vitro experiments are integral to understanding their efficacy and safety. Meanwhile, conjugate vaccines and viral vectors are gaining prominence in disease models, offering potential solutions to antigenic shift and drift. Manufacturing processes are being refined through the adoption of needle-free delivery systems and advances in quality control.

Regulatory approval processes are also undergoing transformation, with data analysis playing a crucial role in ensuring vaccine safety and efficacy. Moreover, the market is witnessing the emergence of next-generation sequencing, which is revolutionizing the understanding of disease surveillance and vaccine efficacy trials. The ongoing research in this field is also addressing concerns related to long-term effects, vaccine hesitancy, and variant-specific vaccines. The market's evolution is further influenced by the ongoing development of DNA vaccines, RNA vaccines, and recombinant vaccines, which are undergoing various phases of clinical trials. The importance of animal models and immunization schedules in the context of herd immunity and global health is also being emphasized.

As the market continues to unfold, it is essential to remain attuned to the evolving patterns and applications across various sectors. The ongoing research in this field is critical to addressing the challenges of infectious diseases and ensuring public health.

How is this Vaccine Research Industry segmented?

The vaccine research industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

End-user

  Public
  Private


Age Group

  Pediatric
  Adult


Technology

  Recombinant Vaccines
  mRNA Vaccines
  Subunit Vaccines
  Live-Attenuated Vaccines
  Inactivated Vaccines
  Viral Vector Vaccines
  Conjugate Vaccines
  Toxoid Vaccines
  Adjuvants


Disease Type

  Infectious Diseases
  Cancer
  Autoimmune Diseases
  Allergies
  Neurological Disorders


Research Phase

  Preclinical Research
  Clinical Trials (Phase I, Phase II, Phase III)
  Discovery & Development


End-User

  Pharmaceutical & Biotechnology Companies
  Academic & Research Institutions
  Contract Research Organizations (CROs)
  Government Agencies


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa

    Egypt
    KSA
    Oman
    UAE


  APAC

    China
    India
    Japan


  South America

    Argentina
    Brazil


  Rest of World (ROW)

By End-user Insights

The public segment is estimated to witness significant growth during the forecast period.

In response to the global health crisis caused by the COVID-19 pandemic, governments have significantly invested in vaccine research and development. Institutions like the US National Institute of Allergy and Infectious Diseases (NIAID) and the US National Institutes of Health (NIH) have been at the forefront of this endeavor. The research p

Snapshot img

Vaccines Market Size 2025-2029

The vaccines market size is forecast to increase by USD 160.22 billion at a CAGR of 23.1% between 2024 and 2029.

The market is experiencing significant growth, driven by increased funding for research and development, leading to the launch of new vaccines. One of the most promising trends in this market is the development of nanoparticle vaccines, which offer enhanced immunogenicity and improved delivery systems. This trend is particularly evident in the development of nanoparticle vaccines, which offer enhanced efficacy and safety. However, the high cost of research, development, and manufacturing poses a significant challenge for market players. Examples include the inactivated polio vaccine (IPV) and influenza vaccine. These costs can be attributed to the complex production processes involved in vaccine creation, as well as the need for rigorous clinical trials to ensure safety and efficacy. 
However, the high cost of vaccine research, development, and manufacturing remains a significant challenge for market participants. Despite this, the market presents numerous opportunities for companies seeking to capitalize on the growing demand for vaccines, particularly in emerging economies with rising healthcare expenditures. Strategic partnerships, collaborations, and acquisitions are key strategies for companies looking to navigate the competitive landscape and stay ahead of the curve.
Overall, the market is poised for continued growth, with significant opportunities for innovation and investment in the coming years. Companies that can effectively address the challenges of cost and regulatory compliance while delivering high-quality, effective vaccines will be well-positioned to succeed.

What will be the Size of the Vaccines Market during the forecast period?

Request Free Sample

The market driven by the continuous development of immunization programs and the pursuit of vaccine equity. Immunological memory, antibody response, and cost-effectiveness analysis are key factors influencing market growth. Vaccine supply chain, efficacy testing, preservation, patent, and licensing are essential aspects of the market. Nanotechnology and universal vaccines are emerging trends, aiming to improve vaccine accessibility and quality control. Vaccine manufacturing, regulatory approval, and economic impact are crucial elements in the market, with intellectual property, vaccine shelf life, and vaccine development pipeline being significant factors.
Vaccine innovation and vaccine safety monitoring are essential for addressing disease burden and ensuring potency, stability, and sterility. Vaccine logistics and vaccine stability are critical for successful distribution and administration, while vaccine safety monitoring emphasizes the importance of ongoing surveillance and immune response assessment. 

How is this Vaccines Industry segmented?

The vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Type

  Subunit vaccines
  Live attenuated vaccines
  Inactivated vaccines
  Toxoid vaccines
  Others


End-user

  Hospitals
  Clinics


Technology

  mRNA vaccines
  Viral vector vaccines
  Protein based vaccines
  DNA vaccines
  Others


Route Of Administration

  Intramuscular
  Subcutaneous
  Oral
  Intranasal
  Others


Disease Type

  Influenza
  Human papillomavirus
  Hepatitis
  Measles
  mumps
  rubella
  Others


Age Group

  Pediatric
  Adult
  Adolescent
  Geriatric


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Type Insights

The subunit vaccines segment is estimated to witness significant growth during the forecast period.

Subunit vaccines, integral components of the healthcare system's disease prevention strategy, employ specific antigenic pieces of a pathogen, such as proteins, sugars, or capsids, to induce a robust immune response. These vaccines, including the mRNA vaccines, are designed to target specific components of the pathogen, making them highly effective in preventing infections. The development process involves identifying and isolating these antigenic components, followed by formulation and rigorous testing to ensure safety and efficacy. For instance, in the realm of disease outbreak prevention, a phase 3 trial for the subunit TB vaccine candidate M72/AS01E was initiated in March 2024 in South Africa.

This trial aims to evaluate the vaccine's efficacy in preventing the progression from latent TB to active pulmonary TB, contributing to herd immunity and ultimately, disease surveillance and vaccine distribution within the healthcare s

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in va

The UK market for vaccines for human medicine is expected to see continued growth over the next decade, driven by increasing demand. Market performance is predicted to expand with a CAGR of +3.9% in volume and +2.6% in value, reaching 2.4K tons and $2.8B respectively by 2035.

UK Pediatric Vaccines Market growth is driven by increasing demand for vaccines, government support for immunization programs, and technological advancements in vaccine formulations and delivery systems.

Forecast: Sold Production of Vaccines for Veterinary Medicine in the UK 2024 - 2028 Discover more data with ReportLinker!

The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. Read More

Snapshot img

Human Combination Vaccines Market Size 2025-2029

The human combination vaccines market size is forecast to increase by USD 7.72 billion, at a CAGR of 8.8% between 2024 and 2029.

The market is characterized by significant growth opportunities and challenges. Key drivers include the increasing prevalence of infectious diseases and the growing awareness of the importance of vaccination in preventing them. However, the market also faces challenges, including the rising threat of antiviral drug resistance, which can reduce the effectiveness of some vaccines. Furthermore, the threat from bioterrorism has led to an increased focus on developing combination vaccines that can protect against multiple diseases simultaneously. Consolidation of different immunization schedules is another trend shaping the market, as healthcare providers seek to simplify vaccine administration and improve patient compliance. Companies in this market must navigate these challenges while capitalizing on the growing demand for combination vaccines to remain competitive and succeed. Effective strategies may include investing in research and development of new combination vaccines, expanding production capacity, and collaborating with healthcare providers to streamline immunization schedules. By addressing these challenges and leveraging market opportunities, companies can position themselves for long-term success in the market.

What will be the Size of the Human Combination Vaccines Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free SampleThe market continues to evolve, driven by the ongoing development of new technologies and applications across various sectors. Pneumococcal disease remains a significant focus, with research and innovation centered around pneumococcal conjugate vaccines, inactivated vaccines, and polysaccharide vaccines. The use of viral vectors, needle-free injection, and immunization programs is expanding, enhancing vaccine access and effectiveness. Market dynamics are shaped by factors such as regulatory approvals, cold chain management, and immunization schedules. Pharmaceutical companies are investing in peptide vaccines, t-cell response, and DNA vaccines, aiming to improve vaccine efficacy and healthcare costs. Market access remains a critical concern, with efforts to address vaccine hesitancy and ensure equitable distribution. The manufacturing process, quality control, and vaccine shelf life are essential considerations, with ongoing research into vaccine delivery systems, recombinant vaccines, and MRNA technology. Health outcomes and healthcare costs are under constant scrutiny, with global health initiatives and vaccination rates playing a crucial role in disease prevention and pandemic preparedness. Vaccine development pipelines are continually evolving, with clinical trials exploring the potential of new adjuvants, vaccine adjuvants, and vaccine effectiveness. The role of intellectual property, disease surveillance, and antibody response in shaping the market landscape is an ongoing discussion. The market's continuous dynamism underscores the importance of staying informed about the latest trends and developments.

How is this Human Combination Vaccines Industry segmented?

The human combination vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments. TypeInactivated vaccineLive attenuated vaccineChannelHospitalsRetailersOnlineRoute Of AdministrationIntramuscularSubcutaneousOralIntradermalNasal sprayGeographyNorth AmericaUSCanadaMexicoEuropeFranceGermanyItalyUKAPACChinaIndiaJapanRest of World (ROW)

By Type Insights

The inactivated vaccine segment is estimated to witness significant growth during the forecast period.The market encompasses a range of vaccine types, including inactivated, live-attenuated, subunit, conjugate, recombinant, peptide, and DNA vaccines. Inactivated vaccines, which account for the largest market share, utilize a process where pathogen particles are destroyed or killed, ensuring they cannot replicate. This segment's dominance is attributed to their better tolerability and fewer complications when combining different antigens. However, producing combination vaccines poses challenges due to potential incompatibilities and interactions among various components. Public awareness campaigns and regulatory approvals play a crucial role in driving the market, with a focus on pandemic preparedness and disease prevention. Vaccine packaging, cold chain management, and storage and stability are essential considerations to maintain vaccine efficacy. Clinical trials, vaccine delivery systems, and quality control are in

Snapshot img

Travel Vaccines Market Size 2025-2029

The travel vaccines market size is forecast to increase by USD 7.05 billion, at a CAGR of 10.7% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing global migration and the changing demographic profile of travelers. With more individuals moving across borders for work, education, or personal reasons, the demand for travel vaccines is on the rise. Additionally, an expanding middle class in developing countries is leading to a rise in international travel, further fueling market growth. However, challenges persist in this market. A notable obstacle is the lack of coverage for travel vaccines in health plans. Examples include the inactivated polio vaccine (IPV) and influenza vaccine.
This issue can limit market penetration and hinder the growth potential for companies in the market. To capitalize on opportunities and navigate these challenges effectively, market players must focus on developing affordable and accessible vaccination solutions for a diverse customer base. By addressing this need, companies can differentiate themselves and gain a competitive edge in the dynamic and evolving market. The rise in international vacations and medical tourism has led to an increase in the number of travelers, thereby driving demand for travel vaccines.

What will be the Size of the Travel Vaccines Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by the constant assessment of disease risks and the need for effective prevention strategies. Booster shot timing and disease prevention are critical considerations, as cold chain logistics ensure the viral load reduction necessary for vaccine efficacy. Quarantine requirements and vaccine interactions necessitate rigorous safety monitoring and disease surveillance, while adverse event profiles and antibody response data inform immunization protocols. Pre-exposure prophylaxis and post-exposure prophylaxis play essential roles in infection control, with adjuvant technology enhancing vaccine potency and herd immunity. Immunogenicity studies and immunization record maintenance are crucial for understanding vaccine efficacy and ensuring proper dosage regimens.

Infection prevention measures, such as travel health insurance and vaccination schedules, rely on risk stratification and pre-travel consultation. Vaccine storage and pathogen inactivation are vital aspects of vaccine delivery systems, while vaccine contraindications and clinical trial data inform vaccine safety and efficacy. Disease surveillance and health advisories help maintain vaccine potency and inform the public of potential risks. The market is expected to grow by over 10% annually, reflecting the ongoing demand for effective disease prevention solutions. For instance, a recent study demonstrated a 95% efficacy rate for a new travel vaccine, highlighting the importance of continuous research and innovation in the field.

By addressing the complexities of disease risk assessment, vaccine interactions, and cold chain logistics, the market continues to unfold, providing vital solutions for individuals and communities alike.

How is this Travel Vaccines Industry segmented?

The travel vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Disease Type

  Influenza
  Diptheria
  Hepatitis
  Typhoid and others


End-user

  Adult vaccines
  Pediatric vaccines


Type

  Outbound
  Inbound


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Disease Type Insights

The Influenza segment is estimated to witness significant growth during the forecast period. The market, specifically for influenza, is experiencing substantial growth due to the revival of leisure and corporate travel, heightened health consciousness among travelers, and the ease of access to influenza shots. Influenza incidence is on the rise and is anticipated to continue increasing during the forecast period. To ensure vaccine efficacy, cold chain logistics play a crucial role in maintaining the required temperature throughout the supply chain. Vaccine interactions and safety monitoring are essential considerations, with clinical trial data and immunization records used to assess vaccine potency and seroprotection rates. However, the high cost of vaccine research, development, and manufacturing remains a significant challenge for market participants.

Adherence to dosage regime

Snapshot img

Influenza Vaccine Market Size 2024-2028

The influenza vaccine market size is forecast to increase by USD 3.76 billion at a CAGR of 8.09% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence and incidence of severe influenza cases, particularly among children. The Global Influenza Program's emphasis on vaccination as a preventative measure is driving market expansion. Combination vaccines, which offer protection against multiple strains of the virus, are gaining popularity due to their convenience and effectiveness. Furthermore, the development of mRNA vaccines, which utilize advanced technology to produce a more potent immune response, is a promising trend in the market. The market for Influenza vaccines encompasses various types, including inactivated vaccines, live attenuated vaccines, quadrivalent vaccines, mono vaccine, trivalent vaccines, pnemucoccol vaccine, pediatric vaccines, and adult vaccines. Despite these advancements, challenges persist, including the difficulty in diagnosing influenza due to its non-specific symptoms and the need for annual revaccination to maintain immunity. Overall, the market is poised for continued growth as the demand for effective vaccines to prevent the spread of influenza remains high.

Market Analysis

Request Free Sample

The market is a significant sector within the global healthcare industry, with a continuous demand due to the seasonal nature of the influenza virus and the ongoing threat of potential pandemics. This market caters to various demographics, including children and adults, through various vaccine types and administration methods. Seasonal influenza vaccines are the primary focus of the market, with two main types: inactivated vaccines and live attenuated vaccines. Inactivated vaccines, also known as flu shots, use killed viruses to stimulate an immune response, while live attenuated vaccines, or nasal sprays, use weakened live viruses.

Furthermore, both types offer protection against the three or four strains of the virus predicted to cause the most significant impact during a season. Quadrivalent vaccines, a more recent addition to the market, protect against an additional B strain, broadening the scope of coverage and potentially reducing the risk of infection. Trivalent vaccines, which protect against three strains, continue to be available and are often used in mass vaccination programs. The pediatric segment of the market is of significant importance due to the vulnerability of children to severe influenza cases. The global influenza program, a collaborative effort between the World Health Organization (WHO) and various national health organizations, plays a crucial role in ensuring the availability of vaccines for children and other at-risk populations.

In addition, combination vaccines, which offer protection against influenza and other diseases, are gaining popularity in the market due to their convenience and potential for reducing the number of vaccinations required. MRNA vaccines, a newer technology, have shown promising results in clinical trials and may become a significant player in the market in the coming years. The market is influenced by several factors, including the severity of seasonal epidemics, the availability and affordability of vaccines, and the public's perception of vaccine efficacy and safety. Hospital and retail pharmacies serve as essential distribution channels for these vaccines, ensuring they reach the end consumer in a timely and convenient manner.

Furthermore, swine flu vaccines, while not a regular component of the seasonal the market, are produced and distributed in response to outbreaks or pandemics. The production and distribution of these vaccines require a rapid response and significant resources, highlighting the importance of a strong global influenza program and the flexibility of vaccine manufacturers. In conclusion, the market is a dynamic and evolving sector within the healthcare industry. With ongoing research and development, the market continues to offer new solutions to protect against the influenza virus, ensuring public health and safety.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Hospitals and pharmacies
  Government and institutional
  Others


Type

  Live attenuated influenza vaccines
  Recombinant influenza vaccines


Geography

  North America

    Canada
    US


  Europe

    UK


  Asia

    China
    India


  Rest of World (ROW)

By Distribution Channel Insights

The hospitals and pharmacies segment is estimated to witness significant growth during the forecast period.The market in the US is categorized by distributio

This publication is an update and extension to the Excel model containing the patient-based sales forecast for COVID-19 vaccines, which was previously covered in Coronavirus Disease 2019 (COVID 19) Vaccines: Opportunity Assessment and Forecast to 2026, published in June 2021. Read More

Forecast: Total Influenza Vaccination Rates in the UK 2022 - 2026 Discover more data with ReportLinker!

In UK Vaccine Glass Packaging Market, The routine vaccination segment is expected to remain a primary consumer of vaccine glass packaging.

In 2024, the UK vaccine market decreased by -15.1% to $2.1B, falling for the second consecutive year after two years of growth. In general, consumption, however, enjoyed moderate growth. As a result, consumption reached the peak level of $7.6B. From 2023 to 2024, the growth of the market remained at a lower figure.

Meningococcal Vaccine Market Outlook

The global meningococcal vaccine market size was valued at approximately USD 3.2 billion in 2023 and is projected to reach USD 6.1 billion by 2032, growing at a CAGR of around 7.6% during the forecast period. This significant growth can be attributed to the rising prevalence of meningococcal disease, increasing awareness about the importance of vaccination, and strong governmental support for immunization programs worldwide.

One of the primary growth factors in the meningococcal vaccine market is the increasing incidence of meningococcal disease, which poses a severe threat to public health. Meningococcal disease can cause life-threatening conditions such as meningitis and septicemia, leading to high morbidity and mortality rates. Governments and health organizations are actively promoting vaccination to prevent outbreaks, thereby driving market growth. Additionally, advancements in vaccine technology have led to the development of more effective and long-lasting vaccines, further boosting market demand.

Another significant growth driver is the rising awareness about meningococcal vaccination. Public health campaigns and educational initiatives have been instrumental in spreading knowledge about the benefits of vaccination among parents, caregivers, and healthcare providers. This increased awareness is leading to higher vaccination rates, especially in developed regions. Moreover, the inclusion of meningococcal vaccines in national immunization schedules has made these vaccines more accessible to the general population, contributing to market expansion.

Governmental and non-governmental funding and support are also crucial factors propelling the market forward. Many countries have implemented vaccination programs that provide meningococcal vaccines at no cost or subsidized rates, thereby encouraging higher uptake. International organizations like the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI) are also playing a significant role in funding vaccination initiatives in lower-income countries, ensuring broader access to these life-saving vaccines.

Regionally, the meningococcal vaccine market is witnessing varied growth patterns. North America holds a substantial market share, driven by high vaccination coverage, robust healthcare infrastructure, and strong governmental support. Europe is also a significant market, with countries like the UK and France actively promoting meningococcal vaccination. The Asia Pacific region is expected to exhibit the highest growth rate due to increasing healthcare expenditure, rising awareness, and the implementation of large-scale immunization programs. On the other hand, the markets in Latin America, and the Middle East & Africa are gradually expanding as awareness and healthcare infrastructure improve.

Vaccine Type Analysis

The meningococcal vaccine market is segmented into four primary types: Polysaccharide Vaccines, Conjugate Vaccines, MenB Vaccines, and Combination Vaccines. Polysaccharide vaccines were among the first types developed to combat meningococcal disease. These vaccines are derived from the polysaccharide coatings of the bacteria and have been effective in controlling outbreaks. However, they are less effective in young children and have a shorter duration of immunity compared to newer vaccine types, which has somewhat limited their usage in recent years.

Conjugate vaccines have gained significant traction due to their superior efficacy and longer-lasting immunity. Unlike polysaccharide vaccines, conjugate vaccines link the polysaccharide to a protein carrier, enhancing the immune response. These vaccines are suitable for use in infants and provide long-term protection, making them a preferred choice in many national immunization programs. The high efficacy of conjugate vaccines against several serogroups of Neisseria meningitidis is a major factor driving their demand.

MenB vaccines are specifically designed to protect against serogroup B meningococcal infections, which are not covered by the traditional polysaccharide and conjugate vaccines. The introduction of MenB vaccines has been a significant advancement in meningococcal disease prevention, particularly in regions where serogroup B is prevalent. These vaccines have proven to be effective in controlling outbreaks and are increasingly being included in immunization schedules across various countries.

Combination vaccines represent the latest innovation in the meningococcal vaccine market. These

Base Year 2023 Forecast Period 2024-2028 Market Growth X.XX%*

The UK veterinary medicine vaccines market dropped to $942M in 2024, which is down by -9.3% against the previous year. Overall, consumption saw resilient growth. Over the period under review, the market reached the maximum level at $1B in 2023, and then shrank in the following year.

The global livestock vaccines market is projected to grow from USD 8.3 billion in 2023 to USD 11 billion by 2028, at a CAGR of 5.8%. The growth is attributed to the increasing demand for safe and effective livestock vaccines to prevent and control diseases in animals. Vaccines for livestock are the major instruments in the health management of animals, which are the key players in disease prevention and control. There are different types of vaccines, for instance, attenuated, inactivated, subunit, and DNA vaccines, all of which are built to provoke the respective immune reactions. The attenuated vaccines have pathogens that are a little weaker than the natural ones, but still, they can be similar to what happens in the natural infection without causing the actual disease. Inert vaccines are made of dead pathogens, which consequently stimulate the immune system without the danger of infection. Subunit vaccines are the ones that have only the necessary antigens, thus they are quite safe and effective. DNA vaccines function by the use of the genetic material that induces immune responses. These vaccines are the main cause of prevention of diseases like foot-and-mouth disease, brucellosis, and avian influenza thus enabling animal welfare, economic stability, and public health safety. Recent developments include: February 2023- Virbac announced the first vaccine for sows to protect the piglets from diarrhea caused by rotavirus and assist pig farmers and veterinarians in the livestock industry., September 2022- Merck Animal Health (Merck & Co., Inc.) signed an agreement to acquire Vence in order to advance technologies in animal health., December 2021- Virbac signed an agreement with Pharmgate to represent itself in the U.S. market for expanded sales in swine segment. This was Virbac’s first footstep in the U.S. market for the swine segment, October 2021- Boehringer Ingelheim International GmbH announced an investment of USD 105.2 million to expand veterinary vaccine capacity in France. , June 2021 – The U.K. announced the setup of a U.K. Animal Vaccine Manufacturing and Innovation Centre in Surrey, for advancing the vaccine development for farm animals and controlling the spread of viral diseases. The government contributed USD 22.8 million to develop this center., February 2021 - Ceva inked a partnership with the French National Research Institute for Agriculture, Food, and Environment (INRAE) for R&D in the improvement of animal health and prevention of diseases from animal origin., January 2021 - Zoetis introduced the Poulvac Procerta HVT IBD vaccine in order to protect poultry against Infectious Bursal Disease., August 2020- Merck Animal Health secured rights to VECOXAN for lambs and calves to prevent them from contracting coccidiosis.. Key drivers for this market are: Rising Prevalence of Disease is Presenting a Large Patient Pool Undergoing Treatment. Potential restraints include: Adverse Effects Assocaited with Vaccines Might Hamper the Market Growth. Notable trends are: Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.

Snapshot img

Pneumococcal Vaccine Market Size 2024-2028

The pneumococcal vaccine market size is forecast to increase by USD 2.85 billion at a CAGR of 5.6% between 2023 and 2028.

The market is witnessing significant growth due to expanding immunization programs by governments in developing countries and advancements in vaccine technologies. These trends are driving the market's growth, as more individuals gain access to these vital vaccines and new innovations improve their efficacy and safety. However, the high cost of vaccine development and production poses a challenge to market growth. Manufacturers must balance the need for affordability with the investment required to bring new vaccines to market. This market analysis report provides a comprehensive overview of these trends and challenges, offering valuable insights for stakeholders looking to capitalize on the opportunities presented by the market.

What will be the Size of the Pneumococcal Vaccine Market During the Forecast Period?

Request Free SampleThe market is witnessing significant growth due to the increasing prevalence of pneumococcal diseases, including pneumonia and invasive pneumococcal disease. These conditions can affect various parts of the body, such as the lungs, bloodstream, and brain covering, leading to complications like bacterial meningitis, sinusitis, and lung disease. Pneumococcal diseases disproportionately affect demographic groups with chronic conditions, such as human immunodeficiency, chronic heart disease, diabetes, and generalized musculoskeletal disorders. The pandemic situation has further highlighted the importance of immunization programs in preventing these diseases. Pipeline studies and research activities are ongoing to develop novel pneumococcal vaccines, particularly protein-based vaccines, to address the prominence of pneumococcal strains causing infections.The economic disparities in vaccine accessibility remain a challenge, with hospitalizations and mortality rates being higher in underserved populations. Despite these challenges, the market is expected to continue its growth trajectory, driven by the increasing awareness of the preventable nature of pneumococcal diseases and the ongoing efforts to improve vaccine manufacturing processes.

How is this Pneumococcal Vaccine Industry segmented and which is the largest segment?

The pneumococcal vaccine industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. TypePneumococcal conjugate vaccinePneumococcal polysaccharide vaccineDistribution ChannelNon-governmental organizationsGovernment authoritiesDistribution partner companiesGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Type Insights

The pneumococcal conjugate vaccine segment is estimated to witness significant growth during the forecast period.

The pneumococcal conjugate vaccine plays a crucial role in preventing infections caused by Streptococcus pneumoniae, a bacterium responsible for pneumonia, meningitis, and sepsis. This vaccine significantly reduces the incidence of pneumonia, particularly among children under five, who were previously at high risk of hospitalization and mortality due to this disease. The global implementation of immunization programs has led to a substantial decrease in pneumonia cases, hospitalizations, and mortality rates. Immunocompromised patients, geriatric population, and those with chronic conditions such as lung disease, chronic heart disease, diabetes, human immunodeficiency, and splenectomy are also at increased risk for pneumococcal diseases. Pneumococcal strains continue to evolve, necessitating ongoing research activities and pipeline studies.The vaccine is administered through various routes, including intramuscular and intradermal injections, and is available at pharmacies, community clinics, and pediatric offices. Common side effects include redness, headache, tiredness, and generalized muscle pain. Protein-based vaccines are also under development to address the prominence of pneumococcal diseases. Despite the success of immunization programs, economic disparities and vaccine accessibility remain challenges.

Get a glance at the Pneumococcal Vaccine Industry report of share of various segments Request Free Sample

The Pneumococcal conjugate vaccine segment was valued at USD 6.71 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 41% to the growth of the global market during the forecast period.

Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request